LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.

    Lim, Sai Kiang / Giebel, Bernd / Weiss, Daniel J / Witwer, Kenneth W / Rohde, Eva

    Stem cells and development

    2020  Volume 29, Issue 14, Page(s) 877–878

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Exosomes ; Humans ; Mesenchymal Stem Cells ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-06-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2142214-X
    ISSN 1557-8534 ; 1547-3287
    ISSN (online) 1557-8534
    ISSN 1547-3287
    DOI 10.1089/scd.2020.0089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3616: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Hicok, Kevin C / Moseley, Timothy

    Stem cells and development

    2020  Volume 29, Issue 14, Page(s) 879–881

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Exosomes ; Humans ; Mesenchymal Stem Cells ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-06-10
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2142214-X
    ISSN 1557-8534 ; 1547-3287
    ISSN (online) 1557-8534
    ISSN 1547-3287
    DOI 10.1089/scd.2020.0095
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3616: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Woods, Peter / Nolan, Anna / Bremer, Nicholas

    Stem cells and development

    2020  Volume 29, Issue 12, Page(s) 747–754

    Abstract: ... of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID ... patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate ... critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall ...

    Abstract This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Betacoronavirus/pathogenicity ; Bone Marrow Cells/cytology ; COVID-19 ; Cell-Derived Microparticles/transplantation ; Cohort Studies ; Coronavirus Infections/mortality ; Coronavirus Infections/therapy ; Critical Illness/mortality ; Critical Illness/therapy ; Exosomes/transplantation ; Female ; Humans ; Male ; Mesenchymal Stem Cell Transplantation/adverse effects ; Mesenchymal Stem Cell Transplantation/methods ; Mesenchymal Stem Cells/cytology ; Mesenchymal Stem Cells/ultrastructure ; Middle Aged ; Pandemics ; Pneumonia, Viral/mortality ; Pneumonia, Viral/therapy ; SARS-CoV-2 ; Severity of Illness Index ; Treatment Outcome
    Keywords covid19
    Language English
    Publishing date 2020-05-12
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2142214-X
    ISSN 1557-8534 ; 1547-3287
    ISSN (online) 1557-8534
    ISSN 1547-3287
    DOI 10.1089/scd.2020.0080
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3616: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Woods, Peter / Nolan, Anna / Bremer, Nicholas

    Stem Cells and Development

    2020  Volume 29, Issue 12, Page(s) 747–754

    Keywords Developmental Biology ; Cell Biology ; Hematology ; covid19
    Language English
    Publisher Mary Ann Liebert Inc
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2142214-X
    ISSN 1557-8534 ; 1547-3287
    ISSN (online) 1557-8534
    ISSN 1547-3287
    DOI 10.1089/scd.2020.0080
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3616: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19"

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Hicok, Kevin C / Moseley, Timothy

    Stem cells dev

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #592089
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19"

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Hicok, Kevin C / Moseley, Timothy

    Stem Cells Dev

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #592089
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al

    Lim, Sai Kiang / Giebel, Bernd / Weiss, Daniel J / Witwer, Kenneth W / Rohde, Eva

    Stem Cells Dev

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #592105
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

    Sengupta, Vikram / Sengupta, Sascha / Lazo, Angel / Woods, Peter / Nolan, Anna / Bremer, Nicholas

    Stem Cells Dev

    Abstract: ... of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe ... cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19 ... patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate ...

    Abstract This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) increase of 192% (P < 0.001). Laboratory values revealed significant improvements in absolute neutrophil count [mean reduction 32% (P value <0.001)] and lymphopenia with average CD3+, CD4+, and CD8+ lymphocyte counts increasing by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. In conclusion, owing to its safety profile, capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19. Future randomized controlled trials (RCTs) are needed to determine ExoFlo therapeutic potential.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #209923
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients.

    Alzahrani, Faisal A / Saadeldin, Islam M / Ahmad, Abrar / Kumar, Dipak / Azhar, Esam I / Siddiqui, Arif Jamal / Kurdi, Bassem / Sajini, Abdulrahim / Alrefaei, Abdulmajeed F / Jahan, Sadaf

    Stem cells international

    2020  Volume 2020, Page(s) 8835986

    Abstract: ... it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes ... MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk ... affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like ...

    Abstract A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease "COVID-19" and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells' sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients.
    Keywords covid19
    Language English
    Publishing date 2020-09-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2573856-2
    ISSN 1687-9678 ; 1687-966X
    ISSN (online) 1687-9678
    ISSN 1687-966X
    DOI 10.1155/2020/8835986
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients

    Faisal A. Alzahrani / Islam M. Saadeldin / Abrar Ahmad / Dipak Kumar / Esam I. Azhar / Arif Jamal Siddiqui / Bassem Kurdi / Abdulrahim Sajini / Abdulmajeed F. Alrefaei / Sadaf Jahan

    Stem Cells International, Vol

    2020  Volume 2020

    Abstract: ... it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes ... MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk ... affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like ...

    Abstract A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease “COVID-19” and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells’ sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients.
    Keywords Internal medicine ; RC31-1245 ; covid19
    Subject code 610
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Hindawi Limited
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top